J Am Acad Child Aadolesc Psychiatry > 자유게시판

Treating and raising kids with ASD poses an enormous burden. Even supposing infantile autism has been first described by Leo Kanner (1) as early as 1943, but the etiology of ASD isn't utterly understood. The genetic background of ASD comprises heterogenic traits (2) which are described to be chargeable for affecting the mind network sign conduction. However, causative treatment options are nonetheless not out there. The illness shows a rise in incidence with climbing numbers up to one out of 54 children (3). While progress has been made in establishing a psychological and symptom adapted remedy, the seek for biologic diagnostic parameters of the disease has grow to be a significant topic in current ASD research.

Several teams from Sweden, UK, and the USA provided invaluable insight to understand the genetic background and threat components for ASD (4-8). While some groups postulate that ASD are extremely familial (7, 8), a closing verdict on the underlying cause of ASD is still far away (2).

A milestone in ASD analysis was the finding that ASD could also be induced by an interplay between genetic predisposition and immunological inflammatory components (9-11). This changed paradigm of ASD conception opened the door to introduce biological (autologous or allogenic) stem cell therapies identified among others for their immune-modulating properties (12, 13). On this context, an increasing number of revealed investigations reporting on therapy makes an attempt employing either autologous or allogeneic bone marrow (BM) or umbilical derived pluripotent cells (14-19) have inspired us to report the leads to a pilot group of children. Autologous BM-derived, level-of-care stem cell transplantation (SCT) was used as a result of the truth that it carries nearly no danger with respect to adversarial autoimmune reaction and for its common availability, as it doesn't exclude children without saved umbilical cord or entry to umbilical cord blood.

Two research making use of intrathecal instillation of autologous stem cells have been reported by Sharma et al. (14) from India and Thanh et al. (15) from Vietnam in small cohorts. To start out a new procedure in a geographical and political part of the world as giant as the EU in our opinion warrants the report of small case studies, which undoubtedly should and might be adopted by larger research in due time. Thus our goal was to contribute to the limited experience acquired to this point by including two elements to the described operative protocol: namely i.v. software of stem cells and the transfusion of bone marrow derived plasma, recognized to be rich in cytokines, and progress elements.

All children obtained state-of-the-art, non-invasive therapy as suggested by their specialists before and after undergoing autologous, level-of-care SCT. For this retrospective case report, consequence was reported by the dad and mom including the Autism Treatment Evaluation Checklist (ATEC) rating, which was completed on-line (https://www.autism.org/autism-remedy-analysis-guidelines/). The ATEC, a questionnaire developed by the Autism Research Institute (San Diego, CA) (6), is widely utilized in publications to explain adjustments over time. ATEC total scores vary from 0 to 179 points and are decided by adding up the 4 sections (part I (0-28 points): speech/language/communication; section II (0-40 factors): sociability; part III (0-36 factors): sensory/cognitive consciousness; and part IV (0-75 factors): health/bodily/behavior). A better rating indicates a higher level of impairment.

The target analysis regarding progress and improvements in ASD encounters numerous difficulties. While there are already numerous diagnostic exams (e.g., Autism Diagnostic Observation Schedule, ADOS; Childhood Autism Rating Scale, Cars; Autism Diagnostic Interview - Revised, ADI-R), progress and improvement are even tougher to assess. Diagnostic exams, similar to ADOS, typically require specialists for execution and the check per se was not developed to check for changes over time. Consequently, we decided to rely on the ATEC rating with all its limitations and advantages as has been achieved in other publications on this discipline (16).

All SCTs were performed as level-of-care procedures in a class IIa operating room with sterile air circulate. The following normal working procedure (SOP) was used: (1) anesthesia was ready with rectal administration of Midazolam (1mg/kg body weight with max. of 15mg); (2) slowly starting sedation with 5-8ml (i.v.) 1%-Propofol (sedoanalgesia); (3) positioning of the patient on one side following surgical washing and draping the anterior and posterior iliac crest; (4) injection of 2ml of 1%-Xylocaine on the planned puncture websites on the periosteum and subcutaneously; (5) aspiration of BM from the posterior and anterior iliac crest adopted by a switch of the BM aspirate to a sterile blood bag; (6) the BM aspirate was then processed in the working room in line with the proprietary protocol using a fully automated cell separator (Sepax S-100; Biosafe S.A., Eysins, CH); (7) after lumbar puncture of the dural sac 2ml of cerebral spinal fluid (CSF) was routinely withdrawn in order to prevent excessive intrathecal pressure secondary to injection of the stem cell concentrate; (8) intrathecal administration of the obtained BM focus (~1ml/10kg body weight); and (9) i.v. administration of the remaining BM concentrate and plasma supernatant (10). Standard postoperative care was utilized.

Samples of BM aspirate/CSF and concentrate were transferred to the same laboratory instantly after SCT and had been analyzed with fluorescence activated cell sorter (FACS) utilizing a stem cell package from Beckman Coulter and the ISHAGE protocol (https://www.bc-cytometry.com/PDF/DataSheet/IM3630.pdf). Stem cell counts together with CD34+ and CD45+/leukocytes, which are often known as oblique indicators for progenitor cells, had been obtained to quantify stem cells.

A summary of demographic, diagnostic, and laboratory information and stem cell transplantation details of the 4 children with ASD are offered in Table 1.

Table 1. Demographic, diagnostic, and laboratory data and stem cell transplantation details of the 4 children with autism spectrum disorder (ASD).

Case Description

Case #1

The birth, a planned caesarean part within the 38th week of pregnancy, of a boy from a 40-12 months-previous wholesome mom and a 41-12 months-previous wholesome father, went without complications. The beginning body weight and length had been 3340g and 51cm, respectively. The youngster developed usually, like his older brother, until the age of two years. Thereafter, the mother and father seen that the boy regularly lost the vocabulary he had already acquired without comorbidity. At 2.5 years of age the baby was non-verbal; thus, speech therapy was started. Because the speech therapy showed no success after about 1.5 years of implementation, the boy was evaluated in a particular clinic for psychiatry and diagnose with autism by Autism Diagnostic Observation Schedule (ADOS) ASD on the age of 4-years.

Immediately after the analysis, the little one started the so-known as ABA (Applied Behavior Analysis) therapy at dwelling (3h/day). Drug therapy with Atomoxetine (8mg oral/day), Risperidone (1mg/ml from 0.5 to 2 x 0.5ml/day), and Cerebrolysin® injection 2 x 2.5ml/week was not started until 6 months after analysis. Despite average cognitive enhancements, there was no change in speech based on the mom and the child was weaned from all remedy. Finally, the dad and mom decided to let the youngster bear autologous SCT in our middle.

The boy showed no minor or serious uncomfortable side effects. The dad and mom observed first impressions of a advantage of the SCT at the 3 months comply with-up evaluation. After a 12 months the youngster improved mainly concerning speech (e.g., the little one began to formulate simple sentences with a number of words, to ask meaningful questions, and eventually to have conversations), social behavior (e.g., he confirmed higher eye contact, obeyed higher, and had no more tantrums), and likewise behavior concerning meals intake and hyperactivity. All accessible, dad and mom-generated ATEC scores are presented in Figure 1A.

Figure 1. Autism remedy evaluation guidelines (ATEC) scores of (A) case #1, (B) case #2, (C) case #3, and (D) case #four earlier than and after stem cell Children's stem cell transplantation (SCT).

Case #2

The single child of a healthy 25-year-outdated mom and a wholesome 31-yr-previous father was born within the 39th week of pregnancy via caesarean section due to umbilical cord malposition across the neck of the youngster. The birth weight was 3600g and the body length 51cm. The primary signs of an ASD (e.g., did not respond to call, shows little eye contact) have been already apparent in the primary 12 months of life. On the age of three the boy was then diagnosed as autistic (F84.0) by a neuropsychiatrist. Dyspraxia (F82) was also found. Drug treatment with Cerebrolysin® injection 1-5ml/week, as well as behavior therapy (2h/day) was applied as recommended by the specialist for just a few years. At the age of 7.5, the language improvement was retarded to the level of a three yr previous youngster. Based on recommendations BM-derived SCT of and exchanges with other parents, the boy's parents determined to have their son treated with autologous SCT.

The child had no minor or critical uncomfortable side effects. Parents noticed vital behavioral modifications regarding hyperactivity, inflexible behavior, but also enhancements with unique digestive issues, sensitivity to noise, and anxiety 9 months after the autologous SCT. Significant behavioral adjustments concerning hyperactivity, inflexible behavior, but also enhancements with authentic digestive problems, sensitivity to noise, and anxiety had been reported by the dad and mom 9 months after the autologous SCT. All available, mother and father-generated ATEC scores are presented in Figure 1B.

Case #three

The boy was born as a single little one to a 30-12 months-old healthy mom and a 35-12 months-outdated healthy father via caesarean section attributable to umbilical cord malpositioning around the neck. The beginning body weight was 4,000g. The mother noticed that her baby boy showed hardly any eye contact, didn't react to names, and showed hardly any social interaction. However, a definitive diagnosis of ASD was made by a psychiatrist later on on the age of 3 years. The child lagged proper speech development; in response to the parents, he understands every little thing, but can't specific himself. He was not handled with any medication nor behavioral therapy as advised by his physicians. The decision of the parents to go for autologous SCT was made at the boy's age of 14.5 years and was additionally based on personal communication with other parents.

The boy confirmed no minor or severe unwanted effects. Despite the advanced age, linguistic (e.g., he started to talk two-phrase sentences) and particularly sensory enhancements similar to perceiving and reacting to the environment were observed by the parents. All out there, dad and mom-generated ATEC scores are introduced in Figure 1C.

Case #4

The one lady on this case series was born as the little sister of a 2-year older boy to a 34-yr-old healthy mom and a 31-yr-previous wholesome father via an elective caesarean section at the 38th week of pregnancy. The delivery weight was 3,180g and the physique length 50cm. The lady developed usually, like his older brother, till the age of 1.5 years, thereafter the mother and father noticed that her habits was not the same because the older sibling (e.g., she was not reacting when known as, no eye contact, not speaking, and she all the time wished to be left alone). With 18 months the child was diagnosed as autistic by a neurologic pediatrician. Additionally, the lady was diagnosed with bronchial asthma requiring inhalation therapy. Immediately after analysis, the child began ABA, which included 3h/day with a specialized psychotherapist and the remaining time ABA was continued together with her mom. Due to only slight enhancements with 2-years of ABA therapy, the mother and father determined to let the little one bear autologous SCT. Deficits existed primarily concerning talking, frustration, and focus.

SCT was performed without any minor or major complications. Three months after the SCT, the girl confirmed improved initiative and learning conduct and was even ready to remember the discovered matter. Furthermore, she has no asthma anymore and the numbers of colds she used to have, considerably decreased. All available, parents-generated ATEC scores are offered in Figure 1D.

Furthermore, mother and father reported that they had been very a lot happy (Case #1 and Case #3) or a lot happy (Case #2 and Case #4) with the procedure and that they'd endure SCT again. This satisfaction correlates with the ATEC rating. Considering an ATEC complete score between 31 and 50 factors as a reasonable type of ASD and values below 30 factors as a mild form, then ASD all cases modified from average to mild form of ASD probably in relation to autologous SCT (Figures 1A-D). No relapse has been observed up to now (1-2 years).

Discussion

With this report we current promising outcomes relating to safety and efficacy suggesting utility of autologous, BM-derived, intrathecally and concurrently intravenously utilized, level-of-care SCT in four children with ASD.

Immediate and Delayed Complications

Using sedation and native anesthesia, the procedure involving BM-biopsy and intrathecal instillation of isolated and concentrated BM stem cells resulted in no rapid or delayed minor or main antagonistic events. That is most certainly attributed to stringent condition current in the operation theatre and expertise of the surgeon and anesthetist. The publish-operative course during the following 48h was uneventful too as preventive non-steroidal anti-inflammatory drug pre-medication and anti-emetics had been prescribed.

Sharma et al. (14) in a group of 34 youngsters reported asides minor uncomfortable side effects including nausea, vomiting, and local ache, a proportion of major antagonistic events in 31% (10/32) comprising hyperactivity and epileptic seizures. Thanh et al. (15) reported no major hostile occasion in equally sized research on 30 children undergoing repeated interventions. In our pilot examine we encountered neither speedy, nor delayed major adversarial occasions.

Assessment of Treatment Outcome

In our small series, therapy final result reported over a follow-up period of 1-1.5 yr relied on the suggestions of the mother and father and ATEC rating. We are aware that dad and mom reporting outcome is topic to bias and to a sure extent on behavioral non-compliance of the children, in our context and just like a randomized managed trial using ATEC as primary endpoint (16), parental-reported ATEC proved to be dependable to assess longitudinal consequence.

Despite the presence of professional ranking tools equivalent to ADOS, Cars, and ADI-R to diagnose and evaluate ASD, such tools could have downside in daily observe. In addition, the dependency on various sources to acquire a extra complete clinical image has been advocated (17).

Diagnostic tests are basically not well suited to judge changes over time and as such do require specialists for execution. Especially in patients with ASD and every day fluctuations, parental assessment with their steady remark of behavioral and developmental changes, may be a significant benefit to single time point assessments.

However, one confounder is that neither standardized check nor parental observations can account for the inherent nature of Ads symptoms and their improvements over time. In our collection, the enrolment of the children to undergo the SCT process was motivated by the frustration of parents a earlier lack of improvement.

Efficacy of the Procedure

Following SCT, reported ATEC scores revealed significant improvements in all ATEC subgroups including speech/communication, social habits, sensory/cognitive awareness, health/bodily/conduct compared to pretreatment status. Such amelioration not solely improved the instant high quality of life of the youngsters and their setting, but can also contribute to the kids's future ability to conduct an unbiased life in a protected surroundings. Hence, from an economical point of view, such improvements could lead to vital reductions of repeatedly incurring care costs with age.

Comparable to our therapy method applying autologous BM-derived intrathecally applied SCT, two investigations -one making use of a single (14) and the opposite two- intrathecal (15) stem cell instillations also reported encouraging outcomes. Mixed outcomes had been reported using intravenous supply of both, autologous or allogenic, umbilical cord blood-derived SCT. Two studies reported significant enhancements (18, 19), while the remaining two solely a development in direction of improvement in a sub-analysis in youngsters with out mental disability (20, 21). Details hereto are summarized in Table 2. Intrathecal software was favored by us on these clinical and in addition theoretical grounds. Stem cells are too giant to cross the blood brain barrier, hence, they must be utilized instantly into the CSF by way of intrathecal route in order to reach the mind.

Table 2. Published investigations reporting intrathecal or intravenous utility of either autologous or allogenic stem cell transplantation for youngsters with autism spectrum disorder (ASD).

An vital detail reported while interviewing the parents was that youngsters began to reply a lot better and faster to their speech and behavior therapy 3-6 months following SCT. Published information suggest that SCT reduces the immunological inflammatory disease of the mind associated with ASD and thus, opens the door for effectiveness of ABA and speech therapy. Indeed, a current proteomic analysis research discovered nine serum proteins to be considerably different in ASD in comparison with usually growing boys and a big correlation with ASD severity in line with ADOS (24). Possible mechanisms for the best way stem cells improve autism have been discussed extra extensively by Liu et al. (25). In abstract, two mechanisms seem to prevail: (a) reset of the immunological system and (b) improved vascular perfusion of the brain, two mechanisms which are addressed both by the stem cells but additionally by the bone marrow plasma, wealthy in development hormones.

There's a large physique of information pointing at immune-related genetically coupled danger elements and events related to ASD. A cascade of occasions, main disruption of neuronal maturation and dysfunctional networking by means of dysfunctional astrocytic neuronal help. A comprehensive review on this topic was recently revealed by Liu et al. (25). More interestingly, neuropathological investigations have recently offered evidence in help of the inflammatory concept, describing perivascular lymphocytic infiltration within the cerebral white, gray matter, and neuronal leptomeninges, this infiltrates had been quantitatively accompanied by a corresponding magnitude of astrocytic activation within the affected areas of the mind. As well as they reported vital loss on neurons and glial cells of the cerebral gray matter immediately adjoining to the leptomeningeal space. Brain micropathology additionally involved periventricular and other cerebral spinal fluid brain interfaces and vascular ependymal constructions, all contributing to a practical disruption of the blood mind barrier (26, 27).

However, in ASD plainly the overexpression of specific histocompatibility (HLA) genes (chromosome 6) and notably activating KIR genes (chromosome 19) play an necessary function in promoting the cellular autoimmune cascade in brain tissue (28). The overexpression of the genes as compared to the final population offers a molecular foundation for understanding events triggering a pathological immune response to viral or microbial antigens. BM-derived SCT is able to concentrating on these pathological processes in the mind with out having immediate and mid-term opposed occasions. The longevity of the effect of BM-derived SCT on suppressing inflammation and derailed autoimmune processes in the central nervous system (29) requires additional investigations in larger cohorts. Furthermore, it's speculated if repeated therapy may have a cumulative effect on ASD. As well as, lengthy-time period commentary are wanted in youngsters following autologous BM-derived SCT, although low likelihood, to rule out potential undesirable complications. Addition issues that require additional elucidation contain (a) the efficacy and security of employed cell types i.e., allogenic vs. autologous, umbilical cord-derived vs. autologous BM-derived, (b) the route of administration (intravenous vs. intrathecal), and (c) the added worth of injecting BM-derived plasma. Presently, the fairly limited accessible literature indicates more favorable results when using intrathecal over intravenous route, in all probability as a result of with the later, most of the cells will probably be filtered by the lung parenchyma during their first blood passage.

Autologous SCT have a biological benefits over allogenic stem cells and resemble a novel and promising therapy choice for autistic youngsters and adolescent not benefiting from typical symptom-based mostly and behavioral therapy. In ASD affected youngsters providing intrathecal SCT at an earlier age needs to be associated with a better benefit, as the mind plasticity and neurogenesis are at their most (30, 31), whereas perivascular damage to the neuronal circuitry is minimal.

Previous findings point out that autologous, BM-derived, intrathecally and concurrently intravenously utilized, level-of-care SCT is a safe therapeutic choice by showing no opposed events. Furthermore, our findings also showed improvements in all four ATEC subsets together with speech/communication, social habits, sensory/cognitive awareness and well being/physical behavior. Our and previous results by other authors are promising, however mandate further investigations in a bigger managed cohort of patients including goal strategies equivalent to biomarkers to probably better perceive the underlying particular person dysfunction and potentially enable a stratification of these patients who may benefit most from this remedy technique.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding writer/s.

Ethics Statement

Ethical overview and approval was not required for the examine on human members in accordance with the local legislation and institutional necessities. Written knowledgeable consent to participate on this research was offered by the contributors' legal guardian/next of kin. Written knowledgeable consent was obtained from the individual(s), and minor(s)' authorized guardian/next of kin, for the publication of any potentially identifiable photographs or information included in this text.

Author Contributions

GK and BL: wrote the first draft of the manuscript and coordinated and supervised knowledge collection. GK: an experienced normal and cardiac surgeon, carried out all SCTs. GK, JZ, CP, and BL: substantially contributed to interpretation of information for the work and critically reviewed and revised the manuscript for important intellectual content material. All authors gave their final approval and agreed to be accountable for all elements of this work guaranteeing its integrity and accuracy.

Conflict of Interest

The authors declare that the research was conducted in the absence of any business or financial relationships that might be construed as a possible conflict of curiosity.

Publisher's Note

All claims expressed in this text are solely those of the authors and don't necessarily signify those of their affiliated organizations, or these of the writer, the editors and the reviewers. Any product that could be evaluated in this text, or declare which may be made by its producer, just isn't assured or endorsed by the writer.

Acknowledgments

We gratefully acknowledge the participation of the parents and for permitting us to be taught from their tales. We want to thank the anesthetist for his outstanding performance in pediatric anesthesia leading to reduce any postoperative negative effects.

1. Kanner L. Autistic disturbances of affective contact. Nerv Child. (1943) 2:217-50.

2. Robinson EB, Neale BM, Hyman SE. Genetic research in autism spectrum disorder. Curr Opin Pediatr. (2015) 27:685-91. doi: 10.1097/MOP.0000000000000278

3. Maenner MJ, Shaw KA, Baio J, Washington A, Patrick M, DiRienzo M, et al. Prevalence of autism spectrum disorder among youngsters aged 8 years - autism and developmental disabilities monitoring community, eleven websites, United States. MMWR. (2020) 69:1-12. https://www.cdc.gov/mmwr/volumes/69/ss/ss6904a1.htm?s_cid=ss6904a1_w (accessed September 20, 2021).

4. Lichtenstein P, Carlstrom E, Rastam M, Gillberg C, Anckarster H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry. (2010) 167:1357-63. doi: 10.1176/appi.ajp.2010.10020223

5. Roland A, Happe F, Price TS, Baron-Cohen S, Polmin R. Phenotypic and genetic overlap between autistic traits and their extremes of the general inhabitants. J Am Acad Child Aadolesc Psychiatry. (2006) 45:1206-14. doi: 10.1097/01.chi.0000230165.54117.41

6. Constantino JN, Todd RD. Autistic traits in the general inhabitants: a twin study. Arch Gen Psychiatry. (2003) 60:524-30. doi: 10.1001/archpsyc.60.5.524

7. Constantino JN, Todorov A, Hilton C, Law P, Zhang Y, Molloy E, et al. Autism recurrence in half siblings: strong support for genetic mechanisms of transmission in ASD. Mol Psychiatry. (2013) 18:137-8. doi: 10.1038/mp.2012.9

8. Constantino JN, Zhang Y, Frazier T, Abbacchi AM, Law P. Siblings recurrence and the genetic epidemiology of artisan. Am J Psychiatry. (2010) 167:1349-56. doi: 10.1176/appi.ajp.2010.09101470

9. Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V, et al. Immunological and autoimmune issues of autism spectrum disorders. J Autoimmun. (2013) 44:1-7. doi: 10.1016/j.jaut.2013.05.005

10. Gesundheit B, Rosenzweig JP. Editorial: autism spectrum disorders (ASD)-trying to find the biological foundation for behavioral signs and new therapeutic targets. Front Neurosci. (2016) 10:607. doi: 10.3389/fnins.2016.00607

11. Gesundheit B, Ashwood P, Keating A, Naor D, Melamed M, Rosenzweig JP. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Med Hypotheses. (2015) 84:169-77. doi: 10.1016/j.mehy.2014.12.016

12. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett. (2007) 108:78-87. doi: 10.1016/j.imlet.2006.10.007

13. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in well being and illness. Nat Rev Immunol. (2008) 8:726-36. doi: 10.1038/nri2395

14. Sharma A, Gokulchandran N, Sane H, Nagrajan A, Paranjape A, Kulkarni P, et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept examine. Stem Cells Int. (2013) 2013:623-875. doi: 10.1155/2013/623875

15. Thanh LN, Nguyen H-P, Ngo MD, Bui VA, Dam PTM, Bui HTP, et al. Outcome of bone marrow mononuclear cell transplantation combined with interventional schooling for autis spectrum disorder. Stem Cells Trans Med. (2021) 10:14-26. doi: 10.1002/sctm.20-0102

16. Whitehouse AJO, Granich J, Alvares G, Busacca M, Cooper MN, Dass A, et al. A randomized managed trial of an iPad-based mostly utility to complement early behavioural intervention in autism spectrum disorder. J Child Psychol Psychiatry. (2017) 58:1042-52. doi: 10.1111/jcpp.12752

17. de Bild A, Oosterling IJ, van Lang NDJ, Systema S, Mideraa RB, van England H, et al. Standardized ADOS scores: measuring severity of autism spectrum disorders in Dutch samples. J Autism Dev Disord. (2011) 41:311-9. doi: 10.1007/s10803-010-1057-0

18. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. (2013) 11:196. doi: 10.1186/1479-5876-11-196

19. Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, et al. Autologous cord blood infusions are secure and feasible in young kids with autism spectrum disorder: outcomes of a single-center part I open-label trial. Stem Cells Transl Med. (2017) 6:1332-9. doi: 10.1002/sctm.16-0474

20. Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and observations from a placebo-controlled, crossover examine to assess use of autologous umbilical cord blood stem cells to improve signs in youngsters with autism. Stem Cells Transl Med. (2018) 7:333-41. doi: 10.1002/sctm.17-0042

21. Dawson G, Sun JM, Baker J, Carpenter K, Compton S, Deaver M, et al. A phase II randomized clinical trial of the security and efficacy of intravenous umbilical cord blood infusion for treatment of kids with autism spectrum disorder. J Pediatr. (2020) 222:164-73. doi: 10.1016/j.jpeds.2020.03.011

22. Sharifzadeh N, Ghasemi A, Afshari JT, Moharari F, Soltanifar A, Talaei A, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: a randomized managed trial. Asia Pac Psychiatry. (2021) 13:e12445. doi: 10.1111/appy.12445

23. Sharma AK, Gokulchandran N, Kulkarni PP, Sane HM, Sharma R, Jose A, et al. Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical examine. Am J Stem Cells. (2020) 9:89-100.

PubMed Abstract | Google Scholar

24. Hewitson L, Mathews JA, Devlin M, Schutte C, Lee J, German DC. Blood biomarker discovery for autism spectrum disorder: a proteomic analysis. PLoS ONE. (2021) 16:e0246581. doi: 10.1371/journal.pone.0246581

25. Liu Q, Chen MX, Sun L, Wallis CU, Zhou JS, Ao LJ, et al. Rational use of mesenchymal stem cells in the remedy of autism spectrum disorders. World J Stem Cells. (2019) 11:55-72. doi: 10.4252/wjsc.v11.i2.55

26. Di Stasio MM, Nagakura I, Nadler MJ, Andreson MP. T-lymphocytes and cytotoxic astrocytic blebs correlate across autism brain. Ann Neuro. (2019) 86:885-98. doi: 10.1002/ana.25610

27. Chaudhuri Ad, Dasgheyb RM, DeVine LR, Bi H, Cole RN, Haughey NJ. Stimulus-dependent modifications in astrocyte-derived extracellular vesicle cargo regulate neuronal excitability. Glia. (2020) 68:128-44. doi: 10.1002/glia.23708

28. Torres AR, Sweeten TL, Cutler A, Bedke BJ, Fillmre M, Stubbs EG, et al. The affiliation and linkage of the HLA-A2 class I allele with autism. Hum Immunol. (2006) 67:346-51. doi: 10.1016/j.humimm.2006.01.001

29. Pardo CA, Farmer CA, Thurm A, Shebl FM, Ilieva J, Kalra S, et al. Serum and cerebrospinal fluid immune mediators in kids with autistic disorder: a longitudinal research. Mol Autism. (2017) 8:1. doi: 10.1186/s13229-016-0115-7

30. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in adult human hippocampus. Nat Med. (1998) 4:1313-7. doi: 10.1038/3305

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, et al. Murine options of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS ONE.

If you have any kind of questions relating to where and how to make use of https://autismtreatmentcare.com/, you can contact us at our own page.